CPG Salon LLC Employs MindBody® software to Personalize Client Experience

MindBody helps CPG enrich client experiences, which in turn, adds value to CPG Managed Salon Solutions

PHOENIX, ARIZONA, USA, July 25, 2017 /EINPresswire.com/ — CPG Salon, LLC dba Curls, Pearls & Gents Salon, a provider of turn-key salon services for retirement communities is pleased to announce it continues to employ MindBody® (NASDAQ: MB) software, at a new location, to guarantee a better client experience and to simplify client transactions throughout all CPG Salon locations.

MindBody® connects 27 million people to 50,000 businesses around the world.

Company member, Kurt Schemers states, “We’re happy to employ MindBody® software as an important tool to ensure our clients and their family members have an indispensable tool that is feature-rich in making life easier for managing account activity."

Schemers further states, “The retirement communities where CPG operates find comfort in knowing that our client billing system is valued-added, uncomplicated to use, accurate, and very handy for their residents and family members to use."

About CPG Salon LLC – http://www.cpgsalon.com
CPG provides turn-key boutique salon services to Retirement Community Providers throughout multiple locations in Metropolitan Phoenix and surrounding cities. Our flagship concept salons Curls, Pearls & Gents focuses on providing excellence in services to retirement communities, building rapport, and addressing senior’s lifestyle needs with a boutique line of quality products and exceptional service.

Bring CPG to your Community today
http://www.cpgsalon.com/CPG-Product-Info-Sheet.pdf

Hear about how CPG can enhance your Community
http://bit.ly/2oguEZc

Hear about CPG Careers
https://t.co/gLN05jpBvw

Tweets – @cpgsalon
Follow us @ FACEBOOK: https://www.facebook.com/cpgsalonllc

© Copyright 2017 – CPG Salon, LLC.
CPG Salon, LLC. – Care Beyond Beauty®

Kurt Schemers
CPG Salon, LLC
(602) 294-9222
email us here


Source: EIN Presswire

Prolong Pharmaceuticals, Interview Released Ahead of Keynote Address at Biosimilars 2017 Summit

Biosimilars & Biobetters 2017

Biosimilars & Biobetters 2017

SMi Group release interview with Glenn Kazo, President and Chief Operating Officer from Prolong Pharmaceuticals

…companies are now finding out that regulators and customers hold a very high standard of ‘similar’ and an even higher standard for “interchangeable"”

— Glenn Kazo, President and COO, Prolong Pharmaceuticals

LONDON, ENGLAND, UNITED KINGDOM, July 25, 2017 /EINPresswire.com/ — SMi Group have released an interview with Glenn Kazo, President and Chief Operating Officer from Prolong Pharmaceuticals, ahead of his presentation at the 8th annual industry summit on Biosimilars & Biobetters this September.

Prolong Pharmaceuticals is a privately held company with portfolio of hematology and oncology products in clinical development. With over 25 years of experience, Glenn Kazo has been very active in the advancement of Biosimilars and BioBetters, both as an industry speaker and in leading several drug development programs. Throughout his career, Glenn has continued an active consulting practice, advising biopharma clients and venture capital firms on corporate strategy and development.

With a focus on Biobetters, his presentation will explore developing the next generation anti-neuropenic factor. Neulasta is one of the most desirable targets for biosimilar development. Glen’s talk will discuss ongoing technical and market challenges to biosimilar versions of Neulasta, neutropenia prevention vs treatment; and the commercial approach to developing ANF-RhoTM.

In the run-up to the event, SMi Group caught up with Glen to discuss in industry developments and on-going challenges in Biosimilars.

“Beginning in 2012, I gave a series of talks called Why ‘BioDifferent Equals BioBetter.’ The underlying theme was that it is much easier to prove that products are different rather than to prove that products are similar. It wasn’t a popular concept – but companies are now finding out that regulators and customers hold a very high standard of ‘similar’ and an even higher standard for “interchangeable.”

The full interview is available to read in the event download centre with further Q&A’s from Celltrion and Bioceros.

SMi’s 8th Annual Biosimilars & Biobetters event will take place on 27th and 28th September 2017 at the Holiday Inn Kensington Forum, London UK.

More information and a detailed agenda featuring talks from Boehringher Ingelheim, Celltrion Healthcare, Gedeon Richter, Teva Pharmaceuticals, Merck Group, QuintilesIMS and the Norwegian Medicines Agency is available at www.biosimilars-europe.com

–end –

Contact Information:
For media enquiries contact Teri Arri on Tel: +44 (0)20 7827 6162 / Email: tarri@smi-online.co.uk
For all other enquires contact the team on Tel: +44 (0)20 7827 6000 or email events@smi-online.co.uk

About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

Teri Arri
SMi Group
2078276000
email us here


Source: EIN Presswire

Influenza Diagnostics Market is expected to reach US$ 700.7 million by 2023

Global Influenza Diagnostics Market information, by type of flu (Type A flu, type B flu, Type C flu), by Test type, by End User – Forecast to 2023

Major Key Players are Alere (US), BD (US), Becton, Dickinson and Company (U.S.), Cepheid (US), bioMérieux SA (France), Hardy Diagnostics(us), LifeSign LLC.(US), Meridian Bioscience, Inc.(US), ”

— Market Research Future

PUNE, MAHARASHTRA, INDIA, July 25, 2017 /EINPresswire.com/ — Market Highlights

The global Influenza Diagnostics market has been evaluated as moderately growing market and it is expected that the market will continue to grow similarly in the near future. The demand for advanced products is growing continuously. Due to changing disease pattern and increasing cases seasonal flu is leading the market growth for influenza diagnostics.

Rapid development in technology and innovation are also major factors for the market growth. The market for Influenza Diagnostics was around US$ 472.2 million in 2016 and is expected to reach US$ 700.7 million at a CAGR of 5.8/% by 2023.

Major Market Players:

• Alere (US),
• BD (US),
• Becton,
• Dickinson and Company (U.S.),
• Cepheid (US),
• bioMérieux SA (France),
• Hardy Diagnostics(us),
• LifeSign LLC.(US),
• Meridian Bioscience, Inc.(US),
• Quidel Corporation (US),
• Roche Molecular Systems Inc.(Switzerland),
• Sekisui Diagnostics (US),

Request a Sample Report @ https://www.marketresearchfuture.com/sample_request/3142

All the major players in this market are focusing and investing on R&D to develop new and advanced product for the influenza diagnosis. Changing healthcare practices and rapid adoption of new techniques by the healthcare professionals for the early diagnosis are creating many opportunities in this market. All the major players are competing with each other to capture major stake in this market. On the other hand, many small companies are also holding small but marginable share in this market are also getting into research and development to create innovative and advanced products for the diagnosis of influenza. These players are adopting the strategy of collaboration, distribution agreements among others to expand their network in emerging and potential markets to increase their global presence.

Taste the market data and market information presented through more than 62 market data tables and figures spread over 88 numbers of pages of the project report. Avail the in-depth table of content TOC & market synopsis on “Influenza Diagnostics Market Research Report –Global Forecast to 2023.”

Access Report Details @ https://www.marketresearchfuture.com/reports/influenza-diagnostics-market-3142

Regional Analysis:
Considering the global scenario of the market, North America is holding the largest market share in global Influenza Diagnostics market in 2016. While the European region captures the second largest share in Global Influenza Diagnostics market. Asia-Pacific will be fastest growing market for Influenza Diagnostics during the forecast period. Middle East and Africa is expected to grow at steady pace during the forecast period.

Segmentation:

Global Influenza Diagnostics Market has been segmented on the basis of type of flu which comprise Type A flu (Seasonal flu, Swine Flu, Bird Flu), type B flu, Type C flu. On the basis of type of test it segmented into Molecular Tests, Rapid Influenza Detection Tests (RIDT), Direct Fluorescent Antibody (DFA) Tests, Nucleic Acid Sequence-based Amplification (NASBA) Tests, Serological Assays, Simple Amplification-based Assays (SAMBA), Loop-mediated Isothermal Amplification-based Assays (LAMP), and Others. Serological assays further sub segmented into Primary Serological tests (Enzyme linked immuno sorben assay (ELISA), Immuno fluorescent antibody technique (IFAT), Radio immuno assay (RIA), Secondary Serological tests (Agglutination tests, Complement fixation tests (CFT), Precipitation tests Serum neutralization tests (SNT), Toxin-antitoxin test), and Tertiary serological tests.

Make an Enquiry @ https://www.marketresearchfuture.com/enquiry/3142

Table of Content

1. Report Prologue
2. Introduction
2.1 Definition
2.2 Scope of the Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
2.3 Market Structure
2.4. Market Segmentation
3. Research Methodology
3.1 Research Process
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
3.5 Forecast Model
4. Market Dynamics
Continued….

Browse Related Statistical Report

The Global connected healthcare market has been evaluated as growing market and expected that the market will touch high growth figures. On the basis of type, the market is segmented into; M-health devices, M-health services and E-prescription. The M-Health Services holds 56.7% market share and expected to reach USD 59.05 billion by 2022 from USD 6.80 billion in 2015. E-prescription is expected to grow at a fastest CAGR of 30.84% from 2016 to 2022.

https://www.marketresearchfuture.com/statistical-reports/connected-healthcare-market-value-2666

About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

Contact Info:
Name: Akash Anand
Organization: Market Research Future
Address: Market Research Future Office No. 524/528,
Phone: +1 646 845 9312
Email: akash.anand@marketresearchfuture.com

Akash Anand
Market Research Future
+1-646-845-9349 (US) / +44 208 133 9349 (UK)
email us here


Source: EIN Presswire

Spartan Micro Announces Appointment of Dr. Donald Frei to its Medical Advisory Board

Spartan Micro, Inc.appointment of Donald Frei, M.D. to its Medical Advisory Board, where he will provide knowledge, insight and advice.

FREMONT, CALIFORNIA, UNITED STATES, July 25, 2017 /EINPresswire.com/ — Spartan Micro, Inc., www.spartanmicro.com,a neurovascular device company, announced the appointment of Donald Frei, M.D. to its Medical Advisory Board. As part of our medical advisory board, Dr. Frei will provide knowledge, insight and advice regarding the following:

• Testing and feedback analysis of prototype and late stage proprietary technologies;
• Prioritizing and implementing product development and initiatives;
• Clinical activities; and,
• Long-range strategy for achieving its mission to create safer more effective neurovascular products.

“Dr. Frei’s addition to the Spartan Micro team increases the strength and knowledge base,” said Eric Stoppenhagen, Chief Executive Officer of Spartan Micro. “His service to SNIS brings an insight to a wide breath of varying practices in the neurointerventional field.”

“I am pleased to be mentoring Spartan Micro. The fast-paced environment where they take an idea to reality is very exciting.” said Dr. Frei. “I look forward to working with them on their next generation products.”
About Donald Frei, M.D.

Dr. Donald Frei received his medical degree from the University of Cincinnati School of Medicine in 1989 and completed a radiology residency at Tulane University, New Orleans, Louisiana in 1994. Additionally, he completed additional training in neuroradiology and endovascular surgical neuroradiology at Washington University/Mallinckrodt Institute of Radiology, St. Louis, Missouri in 1996.

Dr. Frei has been the director of Neuro-Interventional Surgery at Swedish Medical Center in Denver, Colorado since 2001. Swedish Medical Center was the first to be certified as a primary and comprehensive stroke center in Colorado. The 17th comprehensive stroke center certified in the USA. They treat ischemic and hemorrhagic stroke patients from a 6 state region in the western US, including: Colorado, Montana, Wyoming, Kansas, Nebraska and New Mexico. In 2016, we treated over 500 ischemic and hemorrhagic stroke patients.

Dr. Frei has been actively involved in ischemic and hemorrhagic stroke research for many years participating in many clinical trials, including: the ESCAPE trial, Proact I and Proact II, IMS 3, the SWIFT trial, Merci and MULTI Merci trials and the Penumbra Pivotal trial.

Dr. Frei has been on the board of directors for the Society of Neuro-Interventional Surgery (SNIS) for the past 10 years and has served as the President of SNIS since 2015. During his presidency, they have launched a national effort to elevate the systems of care for stroke patients nationwide, called Get Ahead of Stroke (www.getaheadofstroke.org).
Dr. Frei’s life mission: “To advance the care of neurovascular patients through cutting edge research, advocacy and excellent outcomes.”

About Spartan Micro, Inc.
Spartan Micro is a neurovascular medical device company based out of Fremont, California, USA. Its focus is research and development, production and sale of medical devices that will include coil embolics, over-the-wire, flow-guided microcatheters, guiding catheters, neurovascular stents and flow diversion stents.
Spartan Micro is currently developing mechanically detachable embolic coils for the occlusion of cerebral aneurysms. In addition to treating cerebral aneurysms, its coils will also be indicated for use in the peripheral vascular anatomy for occlusion or flow diversion for other vascular deformities.

Forward-looking Statements
This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger, multinational companies, (v) product liability claims, (vi) product malfunctions, (vii) our limited manufacturing capabilities and reliance on subcontractors for assistance, (viii) insufficient or inadequate reimbursement by governmental and other third party payers for our products, (ix) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (x) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (xi) our reliance on single suppliers for certain product components, (xii) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction.

Investor Relations:
Spartan Micro, Inc.
Eric Stoppenhagen
Chief Executive Officer
Phone: 1- 512-270-8501
Email: info@SpartanMicro.com
www.spartanmicro.com

Eric Stoppenhagen
Spartan Micro, Inc.
9499030468
email us here


Source: EIN Presswire

Intravenous Immunoglobulin (Ivig) Market Is poised to grow at Rate Of 5.9% during 2016-2023

Global Intravenous Immunoglobulin (IVIg) Market information, by type (IgA, IgD, IgE, IgG, IgM), by Appliaction – Forecast to 2023

Major Key Players are ABEONA THERAPEUTICS (US), Baxter (US), BDI Pharma (US), Biotest AG.(Germany),, China Biologic Products, Inc. (China), CSL Behring (US), Grifols Inc. (Spain), ”

— Market Research Future

PUNE, MAHARASHTRA, INDIA, July 25, 2017 /EINPresswire.com/ — Market Highlights

The global market for Intravenous Immunoglobulin (IVIg) market is growing continuously and expected to grow at a CAGR of 5.9% from 2016 to 2023. The global Intravenous Immunoglobulin (IVIg) market has been evaluated as moderately growing market and it is expected that the market will continue to grow similarly in the near future. The demand for new products and therapy is growing continuously. The market for Intravenous Immunoglobulin (IVIg) was around US$ 5910.8 million in 2016 and is expected to grow at a CAGR of 5.9% by 2023.

Major Players in market:

• ABEONA THERAPEUTICS (US),
• Baxter (US),
• BDI Pharma (US),
• Biotest AG.(Germany),,
• China Biologic Products, Inc. (China),
• CSL Behring (US),
• Grifols Inc. (Spain),
• Kedrion S.p.A (us),
• Octapharma (Switzerland),
• Shire (Republic of Ireland),

Request a Sample Report @ https://www.marketresearchfuture.com/sample_request/3137

Biotest AG. Was found in 1946 and based in Germany. Biotest AG is one of the key players in the market. This company employed about 2,527 people throughout the world and total revenue of the company is US$ 622.7million in 2016. In May 2017, Biotest AG sold their US therapy business to ADMA Biologics, Inc. and received specified current products and a rights related to first order for distribution of upcoming products of ADMA Biologics, Inc. in Europe and selected parts of Asia and middle East.

Octapharma was founded in 1983. Octapharma is Switzerland based one of the largest human protein product manufacture in the world. This company is in development and production of human proteins for human plasma and human cell line. The total revenue of the company in 2016 was US$ 1.8 billion. Company has more than 7,000 employees throughout the globe. In 2016, Octopharma Plasma, Inc.’s Testing Laboratory received approval from U.S. Food and Drug Administration (FDA).
The Republic of Ireland based company Shire was founded in 1986. Shire is focusing on R&D and production for rare diseases. The total revenue of Shire in 2016 was US4 11.6 billion and was generated US$ 1,516 million from immunology sales. The products of Shire are available in more than 100 countries and has about 23,900 employee strength.

Taste the market data and market information presented through more than 64 market data tables and figures spread over 80 numbers of pages of the project report. Avail the in-depth table of content TOC & market synopsis on “Intravenous Immunoglobulin (IVIg) Market Research Report –Global Forecast to 2023.”

Access Report Details @ https://www.marketresearchfuture.com/reports/intravenous-immunoglobulin-market-3137

Regional Analysis:
Considering the global scenario of the market, North America was holding largest market share in global IVIg market in 2016. While the European market, especially Western Europe is growing and second largest market for Global IVIg. Asia-Pacific will be fastest growing market for IVIg during the forecasted period. Middle East and Africa is expected to grow at steady pace during the forecast period.

Segmentation:
Intravenous Immunoglobulin (IVIg) Market has been segmented on the basis of type which comprise Plaque psoriasis, Scalp psoriasis, Nail psoriasis, Guttate psoriasis, Inverse psoriasis, Pustular psoriasis, Erythrodermic psoriasis and others. Plaque psoriasis is most common type and about 80% of the cases are plaque psoriasis. On the basis of treatment type it segmented into Topical corticosteroids, Vitamin D analogues (Calcipotriene, Calcitriol), Anthralin, Topical retinoids (Retinol, Tretinoin (retinoic acid / retin-A /Steiva-A), Adapalene (Differin), Tazarotene), Calcineurin inhibitors (tacrolimus (Prograf), pimecrolimus (Elidel)), Salicylic acid, Coal tar, Moisturizers, and Others. Vitamin D analogs such as Calcipotriene and Calcitriol very helpful and helps to slow skin cell growth. Topical retinoids like are Retinol, Tretinoin (retinoic acid / retin-A /Steiva-A), Adapalene (Differin), Tazarotene are vitamin A derivatives that helps to reduce inflammation.

Make an Enquiry @ https://www.marketresearchfuture.com/enquiry/3137

Table of Content
1. Report Prologue
2. Introduction
2.1 Definition
2.2 Scope of the Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
2.3 Market Structure
2.4. Market Segmentation
3. Research Methodology
……
7.3 Multifocal Motor Neuropathy
7.4 Immunodeficiency diseases
7.4.1 X-linked agammaglobulinemia (XLA)
7.4.2 Common variable immunodeficiency (CVID)
7.2.4 Severe combined immunodeficiency
7.5 Primary Humoral Immunodeficiency
7.5.1 B cell (antibody) deficiencie
7.5.2 T cell deficiencies
7.5.3 Combination BT cell deficiencies
7.5.4 Defective phagocytes
7.5.5 Complement deficiencies
Continued…..

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

Contact Info:
Name: Akash Anand
Organization: Market Research Future
Address: Market Research Future Office No. 524/528,
Phone: +1 646 845 9312
Email: akash.anand@marketresearchfuture.com

Akash Anand
Market Research Future
+1-646-845-9349 (US) / +44 208 133 9349 (UK)
email us here


Source: EIN Presswire

Tinea Versicolor Treatment Market is expected to reach USD 1107.9 million by 2023

Tinea Versicolor treatment market information, by diagnosis (wood lamp (black light) examination), by treatment, by end user- global forecast till 2023

Major Key Players are Astellas Pharma US, Inc. (Japan), Bayer AG (German), Enzon Pharmaceuticals, Inc. (US), Galderma S.A. (Switzerland), Gilead (US), Novartis AG , Pfizer Inc. (US), ”

— Market Research Future

PUNE, MAHARASHTRA, INDIA, July 25, 2017 /EINPresswire.com/ — Market Highlights

The global tinea versicolor treatment market has been evaluated as a moderately growing market and it is expected to continue growing in the near future. Tinea versicolor is common yeast infection of skin. The prevalence rate is higher in tropical areas and frequency is more during the summer. Increasing prevalence of various skin diseases are key factor for market growth. Some other major factors like increasing awareness, new drug development, clinical trials and approvals, and rising demand from emerging markets of Asia and South America are also driving the global tinea versicolor market.

The market for Tinea Versicolor treatment was around USD 685.4 million in 2016 and is expected to reach USD 1107.9 million by 2023 which is a projected CAGR of 7.1%.

Request a Sample Report @ https://www.marketresearchfuture.com/sample_request/3878

Major players in market:

• Astellas Pharma US, Inc. (Japan),
• Bayer AG (German),
• Enzon Pharmaceuticals, Inc. (US),
• Galderma S.A. (Switzerland),
• Gilead (US),
• Novartis AG (Switzerland),
• Pfizer Inc. (US),
• Taro Pharmaceutical Industries Ltd. (US),
• Teva Pharmaceutical Industries Ltd. (Israel),
• Valeant (Canada),

Regional Analysis:

Considering the global scenario of the tinea versicolor treatment market, there are four main regions, America, Europe, Asia Pacific, and Middle East and Africa. The Americas is holding largest market share. The Americas mainly include North America and South America. North America is very important and highest revenue generator market for tinea versicolor treatment. Asia Pacific is second largest and fastest growing market. Some major factors like increasing awareness of the disease, developing healthcare sector, and rising healthcare expenditure are driving the growth for Asia Pacific tinea versicolor treatment market. Europe tinea versicolor treatment is also growing significantly. Germany, UK, and France are the major markets while Eastern European tinea versicolor treatment market is also growing. Middle East & Africa tinea versicolor treatment market is expected to have limited growth mainly due to lack of awareness of the disease, and limited access to the healthcare facilities. Due to developed healthcare infrastructure and high expenditure on healthcare, Middle East is dominating region as compared to Africa.

Taste the market data and market information presented through more than 60 market data tables and figures spread over 83 pages of the project report. Avail the in-depth table of content TOC & market synopsis on “Tinea Versicolor Treatment Market Research Report–Global Forecast to 2023.”

Report Details @ https://www.marketresearchfuture.com/reports/tinea-versicolor-treatment-market-3878

Segmentation:
Global tinea versicolor treatment market has been segmented on the basis of diagnosis which comprise physical exam, imaging tests, and others. Imaging test is sub-segmented into wood lamp (black light) examination, microscopy using Potassium Hydroxide (KOH), fungal culture, skin biopsy, and others. Skin biopsy is sub-segmented into shave biopsy, punch biopsy, excisional biopsy, and others.

On the basis of treatments, the market has been segmented into antifungal shampoos, antifungal creams, drugs, and others. Antifungal shampoos are sub-segmented into selenium sulfide (selsun) 2.5 percent shampoo, ciclopirox (loprox, penlac) shampoo, ketoconazole (ketoconazole, nizoral, others) shampoo, and others. Antifungal creams are sub-segmented into Selenium sulfide (Selsun) 2.5 percent lotion, Ciclopirox (Loprox, Penlac) cream or gel, Ketoconazole (Ketoconazole, Nizoral, others) cream or gel, and others. Drugs are further sub-segmented into fluconazole (diflucan) tablets or oral solution, and others.

On the basis of end user, it is segmented into dermatology hospital and clinics, medical research centers, academic institutes, and others.

Table of Content

1. Report Prologue
2. Introduction
2.1 Definition
2.2 Scope of the Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
2.3 Market Structure
2.4. Market Segmentation
3. Research Methodology
3.1 Research Process
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
3.5 Forecast Model
4. Market Dynamics
Continued….

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

Contact Info:
Name: Akash Anand
Organization: Market Research Future
Address: Market Research Future Office No. 524/528,
Phone: +1 646 845 9312
Email: akash.anand@marketresearchfuture.com

Akash Anand
Market Research Future
+1-646-845-9349 (US) / +44 208 133 9349 (UK)
email us here


Source: EIN Presswire

Affordable Dental Care from ADS Not Far from Wilmington, Delaware

wilmington dentist

Wilmington residents can find dental implants and dentures in West Chester.

Wilmington, Delaware, residents can find affordable dentures and dental implants in West Chester, PA.

Our implants, dentures, and other solutions are of the highest quality.”

— Dr. Michelle Bernreuther

WEST CHESTER, PENNSYLVANIA, UNITED STATES, July 25, 2017 /EINPresswire.com/ — Whether residents of Wilmington, Delaware, need dental implants or dentures, affordable dental care is close by thanks to Affordable Dental Solutions (ADS) in nearby West Chester, PA.

Dental implants in West Chester start at only $2,000 and include both the abutment and crown, which add a finished look to a patient’s new smile.

In addition, both full and partial dentures can be found close to the Wilmington area. Full dentures are only $495/arch and partial dentures are only $595/arch.

“Although our prices are low,” explains Dr. Michelle Bernreuther, implants professional at ADS in West Chester, “our dental implants, dentures, and other solutions are of the highest quality.”

The new location in West Chester, the fourth location of ADS in Eastern Pennsylvania, is conveniently located only forty minutes from Wilmington, Delaware. Wilmington residents looking for missing tooth solutions should request an appointment today: http://wilmingtonimplants.com/.

About Affordable Dental Solutions: Based in Eastern Pennsylvania, Affordable Dental Solutions is a provider of full dentistry services. For nearly a decade, Affordable Dental Solutions has offered patients procedures such as dental implants, crowns, and dentures at rates much lower than area competitors by utilizing state-of-the-art equipment and by negotiating discounts with implant manufacturing companies. Learn more at http://www.affordabledentalsolutions.com/

Jamie Jaskolka
Affordable Dental Solutions
(484) 948-2900
email us here


Source: EIN Presswire

Americas Cancer Biological Therapy Market Overview, Growth, Share, Revenue and Forecast 2017-2023

Americas Cancer Biological Therapy market by type (Monoclonal Antibodies, Gene Therapy, Colony-Stimulating Factors) by end users – Forecast to 2021

Major key Players include Hoffmann-La Roche AG,GSK,Merck & Co.,Novartis International AG, Inc.,GlaxoSmithKline Plc,Bristol-Myers Squibb,”

— Market Research Future

PUNE, MAHARASHTRA, INDIA, July 25, 2017 /EINPresswire.com/ — Market Highlight
Americas Cancer Biological Therapy market is expected to grow at a CAGR of 5.2% during forecasted period of 2017-2023
Americas Cancer Biological therapy market is expected to grow at a steady rate in coming future. There are number of different types of treatment available in the market like chemotherapy, radiotherapy and different drugs therapy, but every therapy has its minor or major side effects. Biological therapies may overcome the side effects like hair loss, weakened immune system which are caused by the other treatment methods. Success rate of all the therapies are same but biological therapy causes less side effects. Cancer can only be cure during 1st stage with a chances of approximately 40-50%.

Biological therapy involves treatment with the help of living organism. Many biological therapy are available for the treatment of cancer. Gene therapy has got a special attention in last few year. Many development and research are been carried out in this field and it can be a better option for the treatment of the cancer. According to National Cancer Institute, 14 million people are suffering from cancer in 2014 which is expected to increase upto 19 million till 2024. The major driving factor for cancer biological therapy market are introduction of new and better antibody, increasing incidence of cancer and less side effect of biological therapy over other optional therapy.

Request a Sample Copy @ https://www.marketresearchfuture.com/sample_request/591

Key Players for Cancer Biological Therapy Market
• Hoffmann-La Roche AG,
• GSK,
• Merck & Co.,
• Novartis International AG, Inc.,
• GlaxoSmithKline Plc,
• Bristol-Myers Squibb,
• Eli Lilly,
• Amgen Inc.,
• Spectrum Pharmaceuticals, Inc.,
• Seattle Genetics, Inc.,
• Celgene Corporation
• others

Segmentation
Americas Cancer Biological Therapy market has been segmented on the basis of-
• By types which comprises of monoclonal antibodies (Naked monoclonal antibodies, Conjugated monoclonal antibodies, other), interferons, interleukins, cancer growth inhibitors (Tyrosine kinase inhibitors, mTOR inhibitors and Proteasome inhibitors), gene therapy, colony-stimulating factors, targeted therapy, cancer vaccines and others.
• On the basis of end user, market is segmented into hospitals & clinics, cancer research centers, laboratories and others.
• And on the basis of Region market is segmented as US, Canada and Rest of America.

Taste the market data and market information presented through more than 50 market data tables and figures spread in 110 numbers of pages of the project report. Avail the in-depth table of content TOC & market synopsis on “Americas Cancer Biological Therapy Market Research Report- Forecast To 2022

Browse full report @ https://www.marketresearchfuture.com/reports/americas-cancer-biologic-therapy-market

Table of Content

1 Introduction
1.1 Definition
1.2 Scope Of Study
1.2.1 Research Objective
1.2.2 Assumptions & Limitations
1.2.2.1 Assumptions
1.2.2.2 Limitations
1.3 Market Structure:
2 Research Methodology
2.1 Research Process:
2.2 Primary Research
2.3 Secondary Research:
3 Market Dynamics
3.1 Drivers
3.2 Restraints
3.3 Opportunities
3.4 Macroeconomic Indicators
4 Market Factor Analysis
4.1 Porters Five Forces Model
4.2 Bargaining Power Of Suppliers
4.3 Bargaining Power Of Buyers
4.4 Threat Of New Entrants
4.5 Threat Of Substitutes
4.6 Intensity Of Rivalry
5 Market Factor Analysis
Continue………….

Key questions answered in this report
• What will the market size be in 2023 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

Related Report
Global Blood Transfusion Diagnostics Market Information by Type (Instruments, Reagents), By Application (Blood Grouping, disease Screening), By End users (Hospital, laboratories, Blood Banks, Plasma Fractionation Facilities) – Forecast to 2027.Know more about this report @ https://www.marketresearchfuture.com/reports/blood-transfusion-diagnostics-market

About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.
Contact:
Akash Anand,
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
Maharashtra, India
+1 646 845 9312
Email: akash.anand@marketresearchfuture.com

Akash Anand
Market Research Future
+1-646-845-9349 (US) / +44 208 133 9349 (UK)
email us here


Source: EIN Presswire

Global Personal Care Encapsulation Materials Market 2017 Share,Trend,Segmentation and Forecast to 2022

PUNE, INDIA, July 25, 2017 /EINPresswire.com/ — WiseGuyReports.Com Publish a New Market Research Report On – “Global Personal Care Encapsulation Materials Market 2017 Share,Trend,Segmentation and Forecast to 2022”.

This report studies Personal Care Encapsulation Materials in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022.

This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering
AB Specialty Silicones
Lambson
Sumitomo Corporation
Durae Corporation
DuPont
BASF
Biogenoci Co. Ltd.
Korea Particle Technology Inc.
Chongqing Pellets Techniques

Get a Sample Report @ https://www.wiseguyreports.com/sample-request/1409282-global-personal-care-encapsulation-materials-market-professional-survey-report-2017

For more information or any query mail at sales@wiseguyreports.com

By types, the market can be split into
Polysaccharides
Proteins
Lipids
Synthetic Polymers
Polyvinyl Alcohol
Poly(vinylpyrrolidone)

By Application, the market can be split into
Personal Care Products
Comestics
Others

By Regions, this report covers (we can add the regions/countries as you want)
North America
China
Europe
Southeast Asia
Japan
India

If you have any special requirements, please let us know and we will offer you the report as you want.

Report Details @ https://www.wiseguyreports.com/reports/1409282-global-personal-care-encapsulation-materials-market-professional-survey-report-2017

Table Of Contents – Major Key Points

Global Personal Care Encapsulation Materials Market Professional Survey Report 2017
1 Industry Overview of Personal Care Encapsulation Materials
1.1 Definition and Specifications of Personal Care Encapsulation Materials
1.1.1 Definition of Personal Care Encapsulation Materials
1.1.2 Specifications of Personal Care Encapsulation Materials
1.2 Classification of Personal Care Encapsulation Materials
1.2.1 Polysaccharides
1.2.2 Proteins
1.2.3 Lipids
1.2.4 Synthetic Polymers
1.2.5 Polyvinyl Alcohol
1.2.6 Poly(vinylpyrrolidone)
1.3 Applications of Personal Care Encapsulation Materials
1.3.1 Personal Care Products
1.3.2 Comestics
1.3.3 Others
1.4 Market Segment by Regions
1.4.1 North America
1.4.2 China
1.4.3 Europe
1.4.4 Southeast Asia
1.4.5 Japan
1.4.6 India

…….

8 Major Manufacturers Analysis of Personal Care Encapsulation Materials
8.1 AB Specialty Silicones
8.1.1 Company Profile
8.1.2 Product Picture and Specifications
8.1.2.1 Product A
8.1.2.2 Product B
8.1.3 AB Specialty Silicones 2016 Personal Care Encapsulation Materials Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.1.4 AB Specialty Silicones 2016 Personal Care Encapsulation Materials Business Region Distribution Analysis
8.2 Lambson
8.2.1 Company Profile
8.2.2 Product Picture and Specifications
8.2.2.1 Product A
8.2.2.2 Product B
8.2.3 Lambson 2016 Personal Care Encapsulation Materials Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.2.4 Lambson 2016 Personal Care Encapsulation Materials Business Region Distribution Analysis
8.3 Sumitomo Corporation
8.3.1 Company Profile
8.3.2 Product Picture and Specifications
8.3.2.1 Product A
8.3.2.2 Product B
8.3.3 Sumitomo Corporation 2016 Personal Care Encapsulation Materials Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.3.4 Sumitomo Corporation 2016 Personal Care Encapsulation Materials Business Region Distribution Analysis
8.4 Durae Corporation
8.4.1 Company Profile
8.4.2 Product Picture and Specifications
8.4.2.1 Product A
8.4.2.2 Product B
8.4.3 Durae Corporation 2016 Personal Care Encapsulation Materials Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.4.4 Durae Corporation 2016 Personal Care Encapsulation Materials Business Region Distribution Analysis
8.5 DuPont
8.5.1 Company Profile
8.5.2 Product Picture and Specifications
8.5.2.1 Product A
8.5.2.2 Product B
8.5.3 DuPont 2016 Personal Care Encapsulation Materials Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.5.4 DuPont 2016 Personal Care Encapsulation Materials Business Region Distribution Analysis
8.6 BASF
8.6.1 Company Profile
8.6.2 Product Picture and Specifications
8.6.2.1 Product A
8.6.2.2 Product B
8.6.3 BASF 2016 Personal Care Encapsulation Materials Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.6.4 BASF 2016 Personal Care Encapsulation Materials Business Region Distribution Analysis
8.7 Biogenoci Co. Ltd.
8.7.1 Company Profile
8.7.2 Product Picture and Specifications
8.7.2.1 Product A
8.7.2.2 Product B
8.7.3 Biogenoci Co. Ltd. 2016 Personal Care Encapsulation Materials Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.7.4 Biogenoci Co. Ltd. 2016 Personal Care Encapsulation Materials Business Region Distribution Analysis
8.8 Korea Particle Technology Inc.
8.8.1 Company Profile
8.8.2 Product Picture and Specifications
8.8.2.1 Product A
8.8.2.2 Product B
8.8.3 Korea Particle Technology Inc. 2016 Personal Care Encapsulation Materials Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.8.4 Korea Particle Technology Inc. 2016 Personal Care Encapsulation Materials Business Region Distribution Analysis
8.9 Chongqing Pellets Techniques
8.9.1 Company Profile
8.9.2 Product Picture and Specifications
8.9.2.1 Product A
8.9.2.2 Product B
8.9.3 Chongqing Pellets Techniques 2016 Personal Care Encapsulation Materials Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.9.4 Chongqing Pellets Techniques 2016 Personal Care Encapsulation Materials Business Region Distribution Analysis

Continue…….

For more information or any query mail at sales@wiseguyreports.com

Buy 1-User PDF@ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=1409282

ABOUT US:
Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports features an exhaustive list of market research reports from hundreds of publishers worldwide. We boast a database spanning virtually every market category and an even more comprehensive collection of market research reports under these categories and sub-categories.

Norah Trent
WiseGuy Research Consultants Pvt. Ltd.
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Genomics Biomarkers 2017 Global Market Expected to Grow at CAGR Of 17.59% and Forecast to 2021

Wiseguyreports.Com Publish New Market Research Report On-“Genomics Biomarkers 2017 Global Market Expected to Grow at CAGR Of 17.59% and Forecast to 2021”.

PUNE, INDIA, July 25, 2017 /EINPresswire.com/ —

Genomics Biomarkers Market 2017

Executive Summary
A measurable DNA and/or RNA characteristic is an indicator of normal biologic processes, pathogenic processes, and/or response to a therapeutic or other interventions. A genomic biomarker can be used for measuring the expression, function, and regulation of a gene. These biomarkers have characteristics of one or more deoxyribonucleic acid (DNA) and/or ribonucleic acid (RNA).

The analysts forecast the global genomics biomarkers market to grow at a CAGR of 17.59% during the period 2017-2021.

Covered in this report
The report covers the present scenario and the growth prospects of the global genomics biomarkers market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of genomic biomarkers.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Request a Sample Report @ https://www.wiseguyreports.com/sample-request/895584-global-genomics-biomarkers-market-2017-2021

The report, Global Genomics Biomarkers Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
• Roche Diagnostics
• Myriad Genetics
• QIAGEN
• Thermo Fisher Scientific
• Bio-Rad Laboratories

Other prominent vendors
• 23andMe
• Aepodia
• Almac Group
• AROS Applied Biotechnology
• DNAVision
• Epigenomics
• Epistem
• Eurofins Scientific
• Foundation Medicine
• Genomic Health
• Liquid Genomics
• New England Biolabs
• OriGene
• US Biomarkers

Market driver
• Genomics biomarker-based personalized medicine
• For a full, detailed list, view our report

Market challenge
• Delay in time from lab to market
• For a full, detailed list, view our report

Market trend
• Expansion of new business models
• For a full, detailed list, view our report

Key questions answered in this report
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

Complete Report Details @ https://www.wiseguyreports.com/reports/895584-global-genomics-biomarkers-market-2017-2021

Table of Contents

PART 01: Executive summary
PART 02: Scope of the report
• Market overview
• Top-vendor offerings

PART 03: Market research methodology
• Research methodology
• Economic indicators

PART 04: Introduction
• Key market highlights

PART 05: Market landscape
• Market overview
• Market size and forecast
• Five forces analysis

PART 06: Market segmentation by indication
PART 07: Market segmentation by end-user
• Diagnostic and research laboratories
• Hospitals

PART 08: Geographical segmentation
• Genomics biomarkers market in Americas
• Genomics biomarkers market in EMEA
• Genomics biomarkers market in APAC

PART 09: Market drivers
• Increasing low-cost clinical trials in developing countries
• Improving research network infrastructures
• Genomics biomarker-based personalized medicine

PART 10: Impact of drivers
PART 11: Market challenges
• Reproducibility of genomic biomarkers and tests leading to discrepancies
• Delay in time from lab to market
• Reimbursement challenges for genomics biomarkers-based tests

PART 12: Impact of drivers and challenges
PART 13: Market trends
• Improvement in care delivery with advances in genomics technologies
• Expansion of new business models
• Development of affordable genomic biomarkers as diagnostics for tropical diseases
..…..Continued

For accessing accurate and deep understanding and to gain latest insights and key developments in the area of your interest, we also have a list of conferences in which you will be interested in, for more information, cordially check:
https://www.wiseguyreports.com/conferences

For updating knowledge or for thoroughly understanding various terminologies, we also have vast list of seminars for your reference, for more information cordially check:
https://www.wiseguyreports.com/seminars

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire